On June 10, 2025, Eledon Pharmaceuticals increased its authorized shares from 200 million to 300 million and provided exculpation protection to officers after stockholder approval at their Annual Meeting. Additionally, stockholders elected three Class II Directors and ratified the appointment of Deloitte & Touche LLP as auditors.